Stocks and Investing Stocks and Investing
Tue, November 6, 2012

Gena Wang Maintained (BMRN) at Buy with Increased Target to $54 on, Nov 6th, 2012


Published on 2024-10-25 01:01:46 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $46 to $54 on, Nov 6th, 2012.

Gena has made no other calls on BMRN in the last 4 months.



There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Andrew Peters of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $45 on, Monday, August 27th, 2012


These are the ratings of the 3 analyists that currently disagree with Gena


  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $56 on, Monday, November 5th, 2012
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Increased Target to $50 on, Thursday, September 27th, 2012
  • Matthew Harrison of "Morgan Stanley" Maintained at Strong Buy with Increased Target to $52 on, Monday, July 23rd, 2012

Contributing Sources